Liver Cancer - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Liver Cancer - Pipeline Review, H1 2016

Liver Cancer - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Liver Cancer - Pipeline Review, H1 2016
Published Jun 22, 2016
1073 pages — Published Jun 22, 2016
Price US$ 2,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Liver Cancer - Pipeline Review, H1 2016, provides an overview of the Liver Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Liver Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Cancer and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Liver Cancer
- The report reviews pipeline therapeutics for Liver Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Liver Cancer therapeutics and enlists all their major and minor projects
- The report assesses Liver Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Liver Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Liver Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Liver Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing

  
Source:
Document ID
GMDHC7964IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents240
  List of Tables365
  List of Figures411
Introduction421
  Global Markets Direct Report Coverage421
Liver Cancer Overview431
Therapeutics Development442
  Pipeline Products for Liver Cancer Overview441
  Pipeline Products for Liver Cancer Comparative Analysis451
Liver Cancer Therapeutics under Development by Companies4613
Liver Cancer Therapeutics under Investigation by Universities/Institutes592
Liver Cancer Pipeline Products Glance613
  Late Stage Products611
  Clinical Stage Products621
  Early Stage Products631
Liver Cancer Products under Development by Companies6419
Liver Cancer Products under Investigation by Universities/Institutes833
Liver Cancer Companies Involved in Therapeutics Development86170
  4SC AG861
  AB Science SA871
  Acceleron Pharma, Inc.881
  ACROVIS Pharma AG891
  Adaptimmune Therapeutics Plc901
  Aduro BioTech, Inc.911
  Advanced Accelerator Applications S.A.921
  Advenchen Laboratories, LLC931
  Alfact Innovation941
  Alnylam Pharmaceuticals, Inc.951
  American Gene Technologies International Inc.961
  Amgen Inc.971
  AndroScience Corporation981
  APAvadis Biotechnologies Srl991
  Arbutus Biopharma Corporation1001
  ArQule, Inc.1011
  Array BioPharma Inc.1021
  Arrowhead Pharmaceuticals, Inc.1031
  Astex Pharmaceuticals, Inc.1041
  AstraZeneca Plc1051
  AVEO Pharmaceuticals, Inc.1061
  Bayer AG1071
  Beijing Kawin Technology Share-Holding Co., Ltd.1081
  Betta Pharmaceuticals Co. Ltd.1091
  Bio-Cancer Treatment International Limited1101
  BioCancell Ltd1111
  Biogazelle1121
  Biomics Biotechnologies Co., Ltd.1131
  Bioneer Corporation1141
  BioStar Pharmaceuticals, Inc.1151
  Blueprint Medicines Corporation1161
  Boehringer Ingelheim GmbH1171
  Boston Biomedical, Inc.1181
  Can-Fite BioPharma Ltd.1191
  CASI Pharmaceuticals Inc.1201
  CCRP Therapeutics GmbH1211
  Celgene Corporation1221
  Celldex Therapeutics, Inc.1231
  Celprogen, Inc.1241
  Celsion Corporation1251
  China Medical System Holdings Limited1261
  Chiome Bioscience, Inc.1271
  Chipscreen Biosciences Ltd1281
  Chroma Therapeutics Limited1291
  CohBar, Inc.1301
  CytRx Corporation1311
  CZ BioMed Corp1321
  Daiichi Sankyo Company, Limited1331
  Delcath Systems, Inc.1341
  Dicerna Pharmaceuticals, Inc.1351
  Digna Biotech, S.L.1361
  Double Bond Pharmaceutical International AB1371
  Eisai Co., Ltd.1381
  Eli Lilly and Company1391
  Endocyte, Inc.1401
  eTheRNA Immunotherapies NV1411
  Eureka Therapeutics, Inc.1421
  Exelixis, Inc.1431
  F. Hoffmann-La Roche Ltd.1441
  Genelux Corporation1451
  Genoscience Pharma1461
  Genosco1471
  GenSpera, Inc.1481
  GlaxoSmithKline Plc1491
  Golden Biotechnology Corp.1501
  Green Cross Cell Corporation1511
  H3 Biomedicine Inc.1521
  HanAll Biopharma Co., Ltd.1531
  HEC Pharm Co., Ltd.1541
  HitGen LTD1551
  Horizon Pharma Plc1561
  Huperion Sarl1571
  Immunicum AB1581
  Immunitor, Inc.1591
  Immunomedics, Inc.1601
  Immunovative Therapies, Ltd.1611
  IMPACT Therapeutics, Inc.1621
  In-Cell-Art S.A.S.1631
  Incanthera Ltd.1641
  Incuron, LLC1651
  InteRNA Technologies B.V.1661
  Jasco Pharmaceuticals, LLC.1671
  Jenrin Discovery, Inc.1681
  Johnson &Johnson1691
  JW Pharmaceutical Corporation1701
  KAHR medical Ltd.1711
  Karcinolys SAS1721
  Keystone Nano, Inc.1731
  Kite Pharma, Inc.1741
  Komipharm International Co., Ltd.1751
  Kowa Company, Ltd.1761
  Les Laboratoires Servier SAS1771
  Ligand Pharmaceuticals, Inc.1781
  Lixte Biotechnology Holdings, Inc.1791
  Lytix Biopharma AS1801
  MaxCyte, Inc.1811
  MedImmune, LLC1821
  Medivation, Inc.1831
  Medivir AB1841
  Merck &Co., Inc.1851
  Merck KGaA1861
  Merrimack Pharmaceuticals, Inc.1871
  Midatech Pharma Plc1881
  Millennium Pharmaceuticals, Inc.1891
  Mirna Therapeutics, Inc.1901
  Molecular Partners AG1911
  MolMed S.p.A.1921
  MultiCell Technologies, Inc.1931
  Nimbus Therapeutics, LLC1941
  NormOxys, Inc.1951
  Northwest Biotherapeutics, Inc.1961
  Novartis AG1971
  NovaTarg Therapeutics, Inc1981
  Nymox Pharmaceutical Corporation1991
  Omeros Corporation2001
  Omnitura Therapeutics Inc.2011
  Oncolys BioPharma Inc.2021
  OncoMed Pharmaceuticals, Inc.2031
  OncoTherapy Science, Inc.2041
  Oneness Biotech Co., Ltd.2051
  Ono Pharmaceutical Co., Ltd.2061
  Onxeo SA2071
  OPKO Health, Inc.2081
  Oribase Pharma2091
  Otsuka Holdings Co., Ltd.2101
  Panacea Pharmaceuticals, Inc.2111
  Peptinov SAS2121
  Pfizer Inc.2131
  Pharma Mar, S.A.2141
  PharmAbcine, Inc.2151
  PharmaEssentia Corporation2161
  Phosplatin Therapeutics LLC2171
  Polaris Pharmaceuticals, Inc.2181
  Progen Pharmaceuticals Limited2191
  ProMetic Life Sciences Inc.2201
  Provecs Medical GmbH2211
  Provectus Biopharmaceuticals, Inc.2221
  Quimatryx, S.L.2231
  Raptor Pharmaceutical Corp.2241
  RedHill Biopharma Ltd.2251
  Regen BioPharma, Inc.2261
  Regulus Therapeutics Inc.2271
  Rigontec GmbH2281
  Saronic Biotechnology, Inc.2291
  Savoy Pharmaceuticals, Inc.2301
  Shenogen Pharma Group Ltd.2311
  Shenzen SiBiono GeneTech Co., Ltd.2321
  Silence Therapeutics Plc2331
  Sillajen Biotherapeutics2341
  Simcere Pharmaceutical Group2351
  Synovo GmbH2361
  Taiwan Liposome Company, Ltd.2371
  Tara Immuno-Oncology Therapeutics LLC2381
  Targetome2391
  Therapure Biopharma Inc.2401
  Theravectys SA2411
  Tiziana Life Sciences Plc2421
  Toko Pharmaceutical Industries Co., Ltd.2431
  TRACON Pharmaceuticals, Inc.2441
  Transgene Biotek Limited2451
  Tumorend, LLC2461
  UbiVac, LLC2471
  VasGene Therapeutics, Inc.2481
  Vaxon Biotech2491
  Vect-Horus S.A.S.2501
  Verlyx Pharma Inc.2511
  VG Life Sciences, Inc.2521
  Vicus Therapeutics, LLC2531
  Virttu Biologics Limited2541
  Vyriad2551
Liver Cancer Therapeutics Assessment25627
  Assessment by Monotherapy Products2561
  Assessment by Combination Products2571
  Assessment by Target25810
  Assessment by Mechanism of Action26811
  Assessment by Route of Administration2792
  Assessment by Molecule Type2812
Drug Profiles283749
  (etodolac + propranolol hydrochloride) Drug Profile2832
  ABC-294640 Drug Profile2855
  AC-2010 Drug Profile2901
  AC-915 Drug Profile2911
  ACR-488 Drug Profile2921
  AdVince Drug Profile2931
  AG-1103 Drug Profile2941
  AL-3818 Drug Profile2952
  AL-8326 Drug Profile2971
  ALF-2111 Drug Profile2981
  AlloVax Drug Profile2992
  ALN-VSP Drug Profile3014
  AMB-8LK Drug Profile3051
  amcasertib Drug Profile3062
  AMG-337 Drug Profile3082
  Antibodies to Inhibit FRMD4A for Oncology Drug Profile3101
  Antibody to Antagonize Fzd2 Receptor for Hepatocellular Carcinoma Drug Profile3111
  Antisense Oligonucleotide to Inhibit HNF4A for HCV Infection Associated Hepatocellular Carcinoma Drug Profile3121
  Antisense RNAi Oligonucleotide for Hepatocellular Carcinoma Drug Profile3131
  Antisense RNAi Oligonucleotide for Hepatocellular Carcinoma Drug Profile3141
  Antisense RNAi Oligonucleotide for Liver Cancer Drug Profile3151
  Antisense RNAi Oligonucleotide for Liver Diseases Drug Profile3161
  Antisense RNAi Oligonucleotide to Inhibit Beta Catenin for Oncology Drug Profile3171
  antroquinonol Drug Profile3181
  apatinib Drug Profile3193
  APTA-16 Drug Profile3221
  APV-224 Drug Profile3231
  ARQ-092 Drug Profile3243
  ASC-JM.Z1 Drug Profile3271
  atezolizumab Drug Profile32811
  AV-203 Drug Profile3393
  AZ-709 Drug Profile3421
  AZD-9150 Drug Profile3433
  BC-821 Drug Profile3461
  BCT-100 Drug Profile3472
  binimetinib Drug Profile3497
  BLU-554 Drug Profile3562
  BLU-9931 Drug Profile3581
  BPI-9016 Drug Profile3591
  brivanib alaninate Drug Profile3603
  bromopyruvate Drug Profile3631
  buparlisib hydrochloride Drug Profile3645
  cabozantinib s-malate Drug Profile36917
  capmatinib Drug Profile3863
  CC-122 Drug Profile3892
  CCV-3611643 Drug Profile3911
  CDX-1401 Drug Profile3923
  Cellular Immunotherapy for Hepatocellular Carcinoma Drug Profile3951
  Cellular Immunotherapy for Hepatocellular Carcinoma Drug Profile3961
  Cellular Immunotherapy for Hepatocellular Carcinoma Drug Profile3971
  Cellular Immunotherapy for Hepatocellular Carcinoma Drug Profile3981
  Cellular Immunotherapy for Metastatic Hepatocellular Carcinoma Drug Profile3991
  Cellular Immunotherapy for Oncology Drug Profile4001
  Cellular Immunotherapy for Oncology Drug Profile4011

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Liver Cancer - Pipeline Review, H1 2016" Jun 22, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Liver-Cancer-Pipeline-Review-H1-2016-2088-15980>
  
APA:
Global Markets Direct - Market Research. (2016). Liver Cancer - Pipeline Review, H1 2016 Jun 22, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Liver-Cancer-Pipeline-Review-H1-2016-2088-15980>
  
US$ 2,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.